This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

HAEMATO Toekomstige groei

Future criteriumcontroles 1/6

Er wordt voorspeld dat HAEMATO de winst en omzet met respectievelijk 5.8% en 4.4% per jaar zal laten groeien.

Belangrijke informatie

5.8%

Groei van de winst

n/a

Groei van de winst per aandeel

Healthcare winstgroei	27.7%
Inkomstengroei	4.4%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	02 Apr 2024

Recente toekomstige groei-updates

Recent updates

The Strong Earnings Posted By HAEMATO (ETR:HAEK) Are A Good Indication Of The Strength Of The Business

May 24

HAEMATO (ETR:HAEK) Hasn't Managed To Accelerate Its Returns

Nov 17

HAEMATO (ETR:HAEK) Will Be Hoping To Turn Its Returns On Capital Around

May 30

We're Not Very Worried About HAEMATO's (ETR:HAEK) Cash Burn Rate

Mar 08

What Do The Returns At HAEMATO (ETR:HAEK) Mean Going Forward?

Feb 15

Estimating The Fair Value Of HAEMATO AG (ETR:HAEK)

Jan 25

Is Now An Opportune Moment To Examine HAEMATO AG (ETR:HAEK)?

Jan 04

Reflecting on HAEMATO's (ETR:HAEK) Share Price Returns Over The Last Three Years

Dec 14

Winst- en omzetgroeiprognoses

XTRA:HAEK - Toekomstschattingen van analisten en financiële gegevens uit het verleden (EUR Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	303	N/A	N/A	N/A	1
12/31/2025	296	10	8	11	2
12/31/2024	281	9	8	10	3
12/31/2023	270	8	4	6	3
6/30/2023	261	10	10	11	N/A
3/31/2023	254	9	14	16	N/A
12/31/2022	248	8	19	20	N/A
9/30/2022	251	4	21	22	N/A
6/30/2022	254	0	24	24	N/A
3/31/2022	270	3	19	19	N/A
12/31/2021	285	7	14	14	N/A
9/30/2021	280	6	12	12	N/A
6/30/2021	274	5	10	10	N/A
3/31/2021	256	0	12	12	N/A
12/31/2020	238	-5	14	15	N/A
9/30/2020	229	-3	4	5	N/A
6/30/2020	220	-2	-6	-5	N/A
3/31/2020	209	-2	-5	-4	N/A
12/31/2019	198	-1	-4	-3	N/A
9/30/2019	211	-1	0	1	N/A
6/30/2019	224	-1	4	5	N/A
3/31/2019	249	3	2	3	N/A
12/31/2018	274	6	-1	1	N/A
9/30/2018	284	8	N/A	N/A	N/A
6/30/2018	294	10	-4	-3	N/A
3/31/2018	292	8	-7	-6	N/A
12/31/2017	289	7	-10	-8	N/A
9/30/2017	281	8	N/A	N/A	N/A
6/30/2017	272	9	7	8	N/A
3/31/2017	274	10	N/A	10	N/A
12/31/2016	276	11	N/A	13	N/A
9/30/2016	273	9	N/A	N/A	N/A
6/30/2016	271	7	N/A	4	N/A
3/31/2016	250	6	N/A	4	N/A
12/31/2015	230	6	N/A	3	N/A
9/30/2015	210	5	N/A	N/A	N/A
6/30/2015	190	5	N/A	2	N/A
3/31/2015	196	6	N/A	4	N/A
12/31/2014	203	7	N/A	7	N/A
9/30/2014	214	9	N/A	8	N/A
6/30/2014	224	10	N/A	9	N/A
3/31/2014	199	9	N/A	3	N/A
12/31/2013	174	8	N/A	-4	N/A
9/30/2013	126	7	N/A	-3	N/A
6/30/2013	79	7	N/A	-2	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei HAEK ( 5.8% per jaar) ligt boven de spaarquote ( 0.7% ).

Winst versus markt: De winst van HAEK ( 5.8% per jaar) zal naar verwachting langzamer groeien dan de markt German ( 21.1% per jaar).

Hoge groeiwinsten: De winst van HAEK zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van HAEK ( 4.4% per jaar) zal naar verwachting langzamer groeien dan de markt German ( 5.6% per jaar).

Hoge groei-inkomsten: De omzet van HAEK ( 4.4% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van HAEK naar verwachting over 3 jaar hoog zal zijn

This company listing is no longer active

HAEMATO Toekomstige groei

Future criteriumcontroles 1/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus EPS estimates increase by 18%

HAEMATO AG Confirms Guidance for the 2023 Financial Year

Haemato Ag Provides Earnings Guidance for the Year 2023

Consensus EPS estimates increase by 19%

Consensus EPS estimates increase by 22%

Consensus forecasts updated

Recent updates

HAEMATO AG, Annual General Meeting, Jul 16, 2024

What Is HAEMATO AG's (ETR:HAEK) Share Price Doing?

Potential Upside For HAEMATO AG (ETR:HAEK) Not Without Risk

Consensus EPS estimates increase by 18%

The Returns At HAEMATO (ETR:HAEK) Aren't Growing

New minor risk - Earnings quality

New major risk - Revenue and earnings growth

HAEMATO AG Confirms Guidance for the 2023 Financial Year

Haemato Ag Provides Earnings Guidance for the Year 2023

Upcoming dividend of €1.20 per share at 5.2% yield

Consensus EPS estimates increase by 19%

HAEMATO's (ETR:HAEK) Dividend Will Be Increased To €1.20

We Like These Underlying Return On Capital Trends At HAEMATO (ETR:HAEK)

Consensus EPS estimates increase by 22%

HAEMATO AG to Report Q3, 2023 Results on Nov 16, 2023

HAEMATO's (ETR:HAEK) Returns On Capital Are Heading Higher

Consensus forecasts updated

Price target decreased to €33.85

First half 2022 earnings released: EPS: €0.17 (vs €1.35 in 1H 2021)

HAEMATO AG Reaffirms its Earnings Guidance for the full year 2022

Upcoming dividend of €1.10 per share

HAEMATO AG Provides Earnings Guidance for the Year 2022

The Strong Earnings Posted By HAEMATO (ETR:HAEK) Are A Good Indication Of The Strength Of The Business

Price target decreased to €41.17

Full year 2021 earnings: Revenues miss analyst expectations

HAEMATO AG Provides Sales Guidance for the Year 2022

HAEMATO AG Appoints Attila Strauss to the Executive Board of the Company with Effect from April 1, 2022

HAEMATO (ETR:HAEK) Hasn't Managed To Accelerate Its Returns

HAEMATO AG Provides Earnings Guidance for the Year 2021

Upcoming dividend of €1.00 per share

HAEMATO (ETR:HAEK) Will Be Hoping To Turn Its Returns On Capital Around

Full year 2020 earnings released: €2.02 loss per share (vs €0.51 loss in FY 2019)

HAEMATO AG Proposes Dividend Payment

Price target decreased to €38.00

We're Not Very Worried About HAEMATO's (ETR:HAEK) Cash Burn Rate

CEO, CFO & Member of the Executive Board Daniel Kracht has left the company

What Do The Returns At HAEMATO (ETR:HAEK) Mean Going Forward?

New 90-day low: €19.80

HAEMATO AG Announces Board Changes

Estimating The Fair Value Of HAEMATO AG (ETR:HAEK)

HAEMATO AG, Annual General Meeting, Jul 13, 2021

New 90-day high: €24.00

Is Now An Opportune Moment To Examine HAEMATO AG (ETR:HAEK)?

Reflecting on HAEMATO's (ETR:HAEK) Share Price Returns Over The Last Three Years

HAEMATO AG Appoints Patrick Brenske to the Management Board

New 90-day low: €19.00

New 90-day low: €21.00

New 90-day low: €23.10

M1 Kliniken AG (XTRA:M12) completed the acquisition of 48.16% stake in HAEMATO AG (XTRA:HAE) from MPH Health Care AG (XTRA:93M).

Price target lowered to €37.50

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven